About IBDLink
IBDLink is a global initiative created and funded by Pfizer, which seeks to advance care for patients with ulcerative colitis (UC).
We believe this goal can be achieved by focusing on:
- Encouraging multidisciplinary management
- Enhancing dialogues between physicians and patients
- Establishing patient-centric approaches
- Addressing gaps in care
As a part of the IBDLink initiative, this site was created to assist gastroenterologists (GIs) in meeting the needs of their patients with UC.
Multidisciplinary management
Multidisciplinary management focuses on the emotional, professional, and social effects of GI disorders in the patient’s life—including the role other HCPs (social workers, psychologists, dietitians, therapists) can play in supporting treatment of UC.
The Importance of IBDLink
Multiple factors underscore the need for an expanded, dialogue-driven approach to enhancing UC treatment:
-
Limited treatment options can contribute to disease management and quality-of-life issues
-
Patient treatment preferences and psychosocial factors are not always evaluated when making treatment decisions
-
Suboptimal communication between GIs and patients may negatively affect treatment
-
The clinical complexity of UC requires multidisciplinary care, which may not be available in certain medical settings or locations
Register today to participate in IBDLink.
Learn From Global GI Leaders
IBDLink is an initiative of Pfizer, which is led by a global committeea that aims to identify and provide educational content focused on supporting shared decision-making between HCPs and the patients under their care.